<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033877</url>
  </required_header>
  <id_info>
    <org_study_id>VTdaP-01</org_study_id>
    <nct_id>NCT01033877</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults</brief_title>
  <official_title>Immunogenicity and Safety of a Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to a Tetanus and Diphtheria (Td) Vaccine When Given as a Booster Vaccination to Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is a phase III, double-blind, randomised, controlled, multi-centre,
      clinical trial, on the immunogenicity and safety of TdaP vaccine in comparison to Td vaccine
      when given as a booster vaccination to adults who were vaccinated with D, T and wP vaccine
      according to the Danish vaccination programme in their childhood.

      Healthy, adult, female or male volunteers, who completed primary vaccination with diphtheria
      (D), tetanus (T) and whole cell pertussis vaccine (wP), typically during their childhood, is
      the target population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Three co-primary outcome measures: Serum anti-PTx antibody conc. in pre- and post-vac. serum samples</measure>
    <time_frame>one month post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum anti-diphtheria antibody conc. in post-vac. serum samples</measure>
    <time_frame>one month post -vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum anti-tetanus antibody conc. in post-vac. serum samples</measure>
    <time_frame>one month post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Three secondary outcome measures: Local and systemic adverse events reported during one month following the vaccination</measure>
    <time_frame>one month post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-diphtheria antibody conc. in pre-vac. serum samples</measure>
    <time_frame>one month post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-tetanus antibody conc. in pre-vac. serum samples</measure>
    <time_frame>one month post- vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">802</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TdaP vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Td vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TdaP vaccine SSI</intervention_name>
    <description>1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: &gt;= 20 I.U. tetanus toxoid (T), &gt;=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)</description>
    <arm_group_label>TdaP vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Td vaccine SSI</intervention_name>
    <description>1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: &gt;= 20 I.U. tetanus toxoid (T), &gt;=2 I.U. diphtheria toxoid (d)</description>
    <arm_group_label>Td vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy female or male adult of â‰¥ 18 years of age

          2. Completed primary vaccination with diphtheria (D), Tetanus (T) and whole cell
             pertussis (wP) vaccines in Denmark

          3. Signed informed consent

          4. Prepared to grant authorised persons access to medical records

          5. Likely to comply with instructions

        Exclusion Criteria:

          1. Congenital or acquired immunodeficiency or progressive neurologic disease

          2. Uncontrolled epilepsy or progressive encephalopathy

          3. Previous experience of serious adverse reaction(s) after vaccinations with
             diphtheria-, tetanus- acellular or whole cell pertussis- vaccines

          4. Vaccinated with any diphtheria, tetanus or pertussis toxoid containing vaccine within
             5 years before inclusion

          5. Vaccinated with any tetanus toxoid, diphtheria toxoid or diphtheria CRM197 protein
             conjugated vaccine within 5 years before inclusion

          6. Known tetanus-, diphtheria- or pertussis disease/infection within 5 years before
             inclusion

          7. Known hypersensitivity or history of allergic reactions to any of the active or
             inactive constituents of the TdaP or Td vaccines

          8. Vaccinated with a live or inactivated vaccine within 1 month before inclusion

          9. Administration of immune modulating drugs (such as immunoglobulin, systemic
             corticosteroids, blood products, azathioprine, cyclosporine, infliximab) within 3
             months before inclusion

         10. Administration of any investigational drug product or vaccine within 1 month before
             inclusion

         11. Females if pregnant or breastfeeding or not willing to use contraception during the
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgit Thierry-Carstensen, M.Sc. Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Statens Serum Institut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carsten Heilmann, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H:S Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H:S Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>aCROnordic</name>
      <address>
        <city>Hoersholm</city>
        <zip>2970</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunisation, active</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

